Table 3 Details of the unmatched in situ hybridisation cases
Case ID | PathVysion | PharmDx™ | INFORM | CISH | ||||
|---|---|---|---|---|---|---|---|---|
HER2 signals per nucleus | CEP17 signals per nucleus | Ratio | HER2 signals per nucleus | CEP17 signals per nucleus | Ratio | HER2 signals per nucleus | HER2 signals per nucleus | |
20 | 5.6 | 5.3 (P) | 1.1 | 6.2 | 4.0 (P) | 1.6 | 4.9 | 6.4 |
21 | 2.2 | 2.5 | 0.9 | 5.1 | 3.3 (P) | 1.6 | 5.6 | 5.6 |
22 | - | - | - | 4.5 | 2.0 | 2.3 | 3.8 | 3.6 |
24 | 2.6 | 2.5 | 1.0 | 3.3 | 2.6 | 1.2 | 4.3 | Clusters |
25 | 3.7 | 3.8 (P) | 1.0 | 6.2 | 4.0 (P) | 1.6 | 7.7 | 5.5 |
26 | 4.4 | 2.8 | 1.6 | 6.1 | 4.2 (P) | 1.5 | 5.3 | 6.6 |
27 | 3.4 | 2.2 | 1.5 | 3.8 | 2.4 | 1.6 | 4.8 | 3.7 |
28 | 3.8 | 3.7 (P) | 1.0 | 4.0 | 3.4 (P) | 1.2 | 5.7 | 4.9 |
29 | 2.0 | 2.0 | 1.0 | 3.5 | 2.0 | 1.7 | 4.4 | 3.6 |
30 | 4.6 | 3.3 (P) | 1.4 | 5.7 | 3.7 (P) | 1.5 | 5.5 | 3.4 |
32 | 2.0 | 2.5 | 0.8 | 2.0 | 2.0 | 1.0 | 4.2 | 4.9 |
33 | 5.6 | 5.0 (P) | 1.1 | 5.2 | 3.5 (P) | 1.5 | 4.5 | 5.7 |
34 | 3.3 | 2.2 | 1.5 | 3.3 | 2.1 | 1.6 | 4.1 | 2.5 |
35 | 3.1 | 3.5 (P) | 0.9 | 2.8 | 2.7 | 1.0 | 4.2 | 3.3 |